Blue Trust Inc. Sells 1,707 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Blue Trust Inc. lessened its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 54.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,434 shares of the medical equipment provider’s stock after selling 1,707 shares during the quarter. Blue Trust Inc.’s holdings in Lantheus were worth $157,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Silverberg Bernstein Capital Management LLC increased its holdings in shares of Lantheus by 0.4% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock worth $1,834,000 after purchasing an additional 100 shares during the period. UMB Bank n.a. increased its holdings in shares of Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares during the period. GAMMA Investing LLC boosted its position in shares of Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after acquiring an additional 146 shares in the last quarter. Moody National Bank Trust Division boosted its position in Lantheus by 1.1% in the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock valued at $1,203,000 after buying an additional 162 shares in the last quarter. Finally, Retirement Systems of Alabama boosted its position in Lantheus by 0.3% in the first quarter. Retirement Systems of Alabama now owns 86,005 shares of the medical equipment provider’s stock valued at $5,353,000 after buying an additional 226 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 10,481 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $95.50, for a total value of $1,000,935.50. Following the completion of the transaction, the director now owns 454,923 shares in the company, valued at $43,445,146.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Mary Anne Heino sold 10,481 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $95.50, for a total value of $1,000,935.50. Following the completion of the transaction, the director now owns 454,923 shares in the company, valued at $43,445,146.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the transaction, the president now owns 98,980 shares of the company’s stock, valued at $9,540,682.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,981 shares of company stock valued at $2,689,156. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on LNTH. Redburn Atlantic began coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target on the stock. B. Riley upped their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Truist Financial reduced their target price on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Leerink Partners upped their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. Finally, JMP Securities reduced their target price on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Lantheus Trading Up 0.4 %

LNTH opened at $110.30 on Monday. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The company has a market cap of $7.66 billion, a price-to-earnings ratio of 18.08 and a beta of 0.50. The firm has a 50 day simple moving average of $107.32 and a 200 day simple moving average of $93.16.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The firm had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. During the same period in the previous year, the company posted $1.40 EPS. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis. On average, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.